Squarepoint’s Benitec Biopharma BNTC Stock Holding History

Squarepoint’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,045	Closed	-$203K	–	4299
2025 Q4	$203K	Buy	+15,045	New	+$208K	﹤0.01%	3863

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Squarepoint's BNTC Position: Q1 2026 in Review

Squarepoint sold out of Benitec Biopharma (BNTC) in Q1 2026, closing a stake of 15,045 shares — an estimated $203K sold.

Squarepoint first reported a position in BNTC in Q4 2025 and held it in 1 quarter. The position peaked at $203K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Squarepoint reported no remaining Benitec Biopharma position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 15,045 Benitec Biopharma shares in Q1 2026, an estimated $203K.
Squarepoint first reported a position in Benitec Biopharma in Q4 2025 and held it in 1 quarter.
Squarepoint's Benitec Biopharma position peaked at $203K in Q4 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.